Adamis Pharmaceuticals Announces Presentation of Results of a Human Factors Study Conducted With Its Newly Approved Epinephrine ...
SAN DIEGO, Dec. 01, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today the acceptance of a presentation entitled “Human Factors Study of A Newly Approved Epinephrine Prefilled Syringe (Symjepi) for the …